全文获取类型
收费全文 | 21471篇 |
免费 | 1932篇 |
国内免费 | 440篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 1009篇 |
妇产科学 | 212篇 |
基础医学 | 1455篇 |
口腔科学 | 166篇 |
临床医学 | 3684篇 |
内科学 | 4066篇 |
皮肤病学 | 136篇 |
神经病学 | 465篇 |
特种医学 | 532篇 |
外科学 | 954篇 |
综合类 | 4581篇 |
预防医学 | 2428篇 |
眼科学 | 126篇 |
药学 | 2532篇 |
56篇 | |
中国医学 | 1178篇 |
肿瘤学 | 210篇 |
出版年
2024年 | 25篇 |
2023年 | 440篇 |
2022年 | 701篇 |
2021年 | 1515篇 |
2020年 | 1746篇 |
2019年 | 686篇 |
2018年 | 658篇 |
2017年 | 864篇 |
2016年 | 951篇 |
2015年 | 890篇 |
2014年 | 1723篇 |
2013年 | 1739篇 |
2012年 | 1494篇 |
2011年 | 1577篇 |
2010年 | 1078篇 |
2009年 | 974篇 |
2008年 | 837篇 |
2007年 | 962篇 |
2006年 | 834篇 |
2005年 | 710篇 |
2004年 | 766篇 |
2003年 | 778篇 |
2002年 | 322篇 |
2001年 | 251篇 |
2000年 | 182篇 |
1999年 | 172篇 |
1998年 | 122篇 |
1997年 | 116篇 |
1996年 | 99篇 |
1995年 | 89篇 |
1994年 | 81篇 |
1993年 | 54篇 |
1992年 | 76篇 |
1991年 | 58篇 |
1990年 | 34篇 |
1989年 | 35篇 |
1988年 | 37篇 |
1987年 | 31篇 |
1986年 | 17篇 |
1985年 | 21篇 |
1984年 | 16篇 |
1983年 | 14篇 |
1982年 | 14篇 |
1981年 | 9篇 |
1980年 | 11篇 |
1979年 | 8篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1976年 | 5篇 |
1973年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 探讨新生儿肺部超声在早产儿肺部感染评价中的价值。
方法 选取肺部感染早产儿80例为观察组,无肺部感染的早产儿80例为对照组,均给予新生儿肺部超声检查,比较2组肺部超声评分、氧合指数、呼吸指数,比较观察组不同病情、预后患儿肺部超声评分、氧合指数、呼吸指数,分析肺部超声评分和氧合指数、呼吸指数的相关性。
结果 观察组肺部超声评分、氧合指数低于对照组,呼吸指数高于对照组,差异有统计学意义(P<0.05)。观察组极危重患儿肺部超声评分、氧合指数低于危重和非危重患儿,呼吸指数高于危重和非危重患儿,危重患儿肺部超声评分、氧合指数低于非危重患儿,呼吸指数高于非危重患儿,差异有统计学意义(P<0.05)。肺部超声评分与呼吸指数呈负相关(r=-0.455,P<0.05),与氧合指数呈正相关(r=0.470,P<0.05)。观察组死亡患儿肺部超声评分、氧合指数低于存活患儿,呼吸指数高于存活患儿,差异有统计学意义(P<0.05)。肺部超声评分预测患儿预后的ROC曲线下面积为0.874,高于呼吸指数和氧合指数(P<0.05),其截断值为20分时,敏感度和特异度为88.50%和75.00%。
结论 新生儿肺部超声在早产儿肺部感染评价中有较好的效果,值得临床使用。 相似文献
2.
[摘要] 目的 对发热伴血小板减少综合征(severe fever with thrombocytopenia syndrome, SFTS)的相关文献进行文献计量学和可视化分析,探寻近年来的研究现状、热点及趋势,为临床治疗和基础研究提供参考。方法?以Web of Science(WOS)核心合集和中国知网(China national knowledge infrastructure, CNKI)数据库为文献来源,检索2011年1月1日—2021年12月31日有关SFTS的文献,导入CiteSpace.5.7.R2软件,以国家、作者、文献共被引、关键词为节点进行可视化分析,并绘制相关图谱。结果?在WOS核心合集共检索到797篇文献,在CNKI数据库共检索到714篇文献。相关领域发文量总体呈上升趋势,中国发文量居首位,美国和日本之间机构合作密切。研究热点集中在发病机制、抗体、特异性治疗等领域。非结构蛋白、临床预后、血小板减少、SFTS感染的靶细胞等将是未来的研究重点。结论?国内外关于SFTS的研究逐渐成熟,新型布尼亚病毒、免疫功能、预后是研究重点,但是对SFTS发病机制和病毒受体尚不清楚,仍须进一步探索。 相似文献
3.
4.
5.
Childhood community acquired pneumonia (CAP) is the leading cause of mortality in children under 5 years worldwide. Clinical practice guidelines (CPGs) may be limited by method of development, scope of recommendations and the quality of supporting evidence. This study systematically identified, appraised and compared the recommendations of CPGs for the management of paediatric CAP using the AGREE II tool.The systematic review yielded 1409 non-duplicate results, of which 14 CPGs were appraised. Four of the fourteen CPGs were deemed high quality. Most CPGs were considered low-medium quality with ‘rigour of development’ and ‘applicability’ the weakest domains. These areas should be considered in deriving CPGs in the future. Recommendations were generally similar across all guidelines; however, there was notable heterogeneity in three areas. This suggests the need for further evidence to guide management decisions on oxygen saturation thresholds for admission, the utility of investigations such as acute phase reactants, and the duration of antibiotic therapy. 相似文献
6.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献
7.
背景严重精神障碍患者因自知力欠缺及高复发性、高致残性等特点,对社会稳定造成严重威胁。做好社区面访管理工作意义重大,通过定期面访患者本人,可以更好地综合评估患者病情,以便及时采取措施,提高管理服务质量。目的了解社区严重精神障碍患者规律面访情况及其影响因素,为提高社区患者的面访服务管理质量提供参考依据。方法2020年10—12月,利用2019年底江苏省严重精神障碍管理系统中建档管理的无锡市严重精神障碍患者基础档案及随访管理信息,分析当年度无锡市社区严重精神障碍患者规律面访情况,采用Logistic回归分析规律面访的影响因素。结果共纳入27 778例研究对象,其规律面访率为81.08%(22 523/27 778)。Logistic回归分析结果显示,非本地户籍〔OR(95%CI)=0.704(0.640,0.775)〕、年龄≤44岁〔OR(95%CI)=0.522(0.472,0.578)〕、学历为高中及以上〔高中/中专OR(95%CI)=0.493(0.446,0.545),大专及以上OR(95%CI)=0.470(0.415,0.532)〕、目前有正式工作〔OR(95%CI)=0.715(0.668,0.766)〕、未婚〔OR(95%CI)=0.746(0.665,0.838)〕、经济状况为非贫困〔OR(95%CI)=0.587(0.517,0.666)〕、没有进行抗精神病药物治疗〔OR(95%CI)=0.491(0.440,0.548)〕、服药时长0~10年〔OR(95%CI)=0.881(0.778,0.998)〕、不是"以奖代补"监护补助对象〔OR(95%CI)=0.807(0.704,0.926)〕、不参加社区康复服务〔OR(95%CI)=0.844(0.716,0.996)〕是患者规律面访的消极影响因素(P<0.05)。结论无锡市社区严重精神障碍患者规律面访率尚需进一步提高,应重点关注非本地户籍、年龄≤44岁、高中及以上学历、目前有正式工作、未婚、经济非贫困、没有进行抗精神病药物治疗、服药时长0~10年、不是监护补助对象和不参加社区康复服务的社区严重精神障碍患者。可通过制定倾斜性政策、开展宣传教育、降低患者病耻感、改善患者疾病认知、加强患者社会支持等措施提高患者规律面访率。 相似文献
8.
[摘要] 目的 对发热伴血小板减少综合征(severe fever with thrombocytopenia syndrome, SFTS)的相关文献进行文献计量学和可视化分析,探寻近年来的研究现状、热点及趋势,为临床治疗和基础研究提供参考。方法?以Web of Science(WOS)核心合集和中国知网(China national knowledge infrastructure, CNKI)数据库为文献来源,检索2011年1月1日—2021年12月31日有关SFTS的文献,导入CiteSpace.5.7.R2软件,以国家、作者、文献共被引、关键词为节点进行可视化分析,并绘制相关图谱。结果?在WOS核心合集共检索到797篇文献,在CNKI数据库共检索到714篇文献。相关领域发文量总体呈上升趋势,中国发文量居首位,美国和日本之间机构合作密切。研究热点集中在发病机制、抗体、特异性治疗等领域。非结构蛋白、临床预后、血小板减少、SFTS感染的靶细胞等将是未来的研究重点。结论?国内外关于SFTS的研究逐渐成熟,新型布尼亚病毒、免疫功能、预后是研究重点,但是对SFTS发病机制和病毒受体尚不清楚,仍须进一步探索。 相似文献
9.
《Vaccine》2022,40(24):3380-3388
BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110. 相似文献
10.
Jerzy Klijanienko MD PhD Béatrix Cochand-Priollet MD PhD Wiktoria Król-Cieciorowska Michał Jeleń MD PhD Danijela Vrdoljak-Mozetič MD PhD 《Cancer cytopathology》2022,130(7):488-490
The 43rd European Congress of Cytology in Wrocław, Poland, was held as a hybrid meeting in the Fall of 2021. After nearly 2 years without in-person cytology conferences, the 43rd Congress represents 1 of the first major international scientific meetings to occur during the severe acute respiratory syndrome-coronavirus 2 pandemic. Since March 2020, the pandemic situation substantially modified the organization of scientific meetings because of both domestic and international travel restrictions, new health standards, and concern among participants, resulting in new alternative forms of virtual conferencing. Cancer (Cancer Cytopathol) 2022;130:000-000. ; 相似文献